These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22854688)

  • 21. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population.
    Islam MS; Ahmed MU; Sayeed MS; Maruf AA; Mostofa AG; Hussain SM; Kabir Y; Daly AK; Hasnat A
    Clin Chim Acta; 2013 Feb; 416():11-9. PubMed ID: 23178447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
    Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
    Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
    Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
    Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
    Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
    Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Association between genotype and allele frequencies of CYP2A6*12 and rs16969968 in CHRNA5 variants with smoking and body mass index in young subjects from Northeast Mexico].
    Borrego-Soto G; Costilla-Esquivel A; Padilla-Rivas GR; Cázares-Samaniego PJ; Posadas-Valay R; Velasco-Castañón JG; Mercado-Longoria R; Ortiz-López R; Rojas-Martínez A
    Rev Med Chil; 2015 Nov; 143(11):1377-85. PubMed ID: 26757861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults.
    Ando M; Hamajima N; Ariyoshi N; Kamataki T; Matsuo K; Ohno Y
    J Epidemiol; 2003 May; 13(3):176-81. PubMed ID: 12749606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption.
    Tyndale RF; Pianezza ML; Sellers EM
    Nicotine Tob Res; 1999; 1 Suppl 2():S63-7; discussion S69-70. PubMed ID: 11768189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population.
    Ohmoto M; Takahashi T; Kubota Y; Kobayashi S; Mitsumoto Y
    BMC Genet; 2014 Dec; 15():151. PubMed ID: 25526961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians.
    Vasconcelos GM; Struchiner CJ; Suarez-Kurtz G
    Pharmacogenomics J; 2005; 5(1):42-8. PubMed ID: 15534625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of CYP2A6 gene polymorphisms with cigarette consumption: a meta-analysis.
    Pan L; Yang X; Li S; Jia C
    Drug Alcohol Depend; 2015 Apr; 149():268-71. PubMed ID: 25683822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2A6 gene polymorphism and personality traits for NEO-FFI on the smoking behavior of youths.
    Waga C; Iwahashi K
    Drug Chem Toxicol; 2007; 30(4):343-9. PubMed ID: 17934923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2A6 genotype and smoking behavior in current smokers screened for lung cancer.
    Styn MA; Nukui T; Romkes M; Perkins KA; Land SR; Weissfeld JL
    Subst Use Misuse; 2013 May; 48(7):490-4. PubMed ID: 23528144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetics and smoking behavior.
    Schnoll RA; Johnson TA; Lerman C
    Curr Psychiatry Rep; 2007 Oct; 9(5):349-57. PubMed ID: 17915073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2A6 Effects on Subjective Reactions to Initial Smoking Attempt.
    Cannon DS; Mermelstein RJ; Medina TR; Pugach O; Hedeker D; Weiss RB
    Nicotine Tob Res; 2016 May; 18(5):637-41. PubMed ID: 26541911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers.
    Chenoweth MJ; Sylvestre MP; Contreras G; Novalen M; O'Loughlin J; Tyndale RF
    Drug Alcohol Depend; 2016 Jan; 158():139-46. PubMed ID: 26644138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin.
    Burian M; Freudenstein J; Tegtmeier M; Naser-Hijazi B; Henneicke-von Zepelin HH; Legrum W
    Int J Clin Pharmacol Ther; 2003 Apr; 41(4):141-7. PubMed ID: 12708602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.
    Bloom AJ; Baker TB; Chen LS; Breslau N; Hatsukami D; Bierut LJ; Goate A
    Hum Mol Genet; 2014 Jan; 23(2):555-61. PubMed ID: 24045616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and environmental influences on therapeutic and toxicity outcomes: studies with CYP2A6.
    Satarug S; Tassaneeyakul W; Na-Bangchang K; Cashman JR; Moore MR
    Curr Clin Pharmacol; 2006 Sep; 1(3):291-309. PubMed ID: 18666753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
    Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
    Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome.
    Ruwali M; Pant MC; Shah PP; Mishra BN; Parmar D
    Mutat Res; 2009 Oct; 669(1-2):36-41. PubMed ID: 19406142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.